ReviewMass spectrometry reviews
Defining Spectral Quality in Mass Spectrometry-Based Proteomics: A Retrospective Review.
Review in Mass spectrometry reviews. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mass spectrometry-based proteomics is essential for advancing preventive and personalised medicine. Technological advancements have greatly increased both the number and sensitivity of spectra generated in a single experiment. Traditionally, spectra are identified using database search engines that depend on large and continuously expanding databases. This expansion enlarges the search space, posing challenges for controlling the false discovery rate in peptide identification. While many bioinformatic workflows employ rescoring algorithms as a post-processing step to manage false discoveries, preprocessing spectra offers a promising alternative. One such method, spectral quality assessment, classifies spectra as "high" quality (likely containing a peptide) or "low" quality (predominantly consisting of noise). This review provides a comprehensive perspective on spectral quality assessment, examining existing tools and their underlying principles. We discuss key considerations such as the definition of spectral quality, normalisation, the use of experimental training data, and future research in the field. By highlighting the potential of spectral quality assessment to improve peptide identification and reduce false discoveries, we aim to elaborate on its potential for the proteomics community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.